Forecast

Buy	5
Hold	0
Sell	0

News Go to news feed

Lineage Cell Therapeutics advances preclinical pipeline and extends cash runway to Q3 2028

Lineage reported preclinical progress in corneal disease, Type 1 diabetes and hearing-loss programs while Roche and Genentech continue optimizing surgical delivery for lead OpRegen. The OPC1 DOSED study has treated two chronic spinal-cord-injury patients with no unexpected safety issues, though it is not designed to assess efficacy. Lineage highlighted its AlloSCOPE manufacturing platform aimed at scalable allogeneic production and said existing GMP banks have been FDA-cleared and used in OpRegen trials. The company ended Q2 with $50.8 million in cash and marketable securities, extending its expected runway into Q3 2028, and remains eligible for up to $615 million in milestones plus tiered royalties from the Roche/Genentech deal. » More on finance.yahoo.com
Lineage Cell Therapeutics reports Q2 profit and extends financing through Q3 2028

Lineage Cell Therapeutics reported a net profit of $1.5 million in the second quarter of 2026 on revenue that fell to $1.1 million. Cash and marketable securities amounted to $50.8 million as of June 30, which the company says finances operations through the third quarter of 2028. The reported gain was largely non‑cash, stemming from a revaluation of option-related liabilities, while operating activities still showed a loss of $8.9 million. Management emphasizes the “Lineage 3.0” platform strategy and points to ongoing partnerships such as OpRegen with Roche/Genentech, as well as expected pipeline updates before the end of 2026. » More on de.investing.com
Lineage Cell Therapeutics files prospectus supplement for stock offering of up to $60 million

Lineage Cell Therapeutics has filed a prospectus supplement with the SEC for the potential sale of common stock totaling up to $60 million. The shares would be offered from time to time under an existing distribution agreement with B. Riley Securities; the supplement is part of an existing shelf registration (Form S-3). The company emphasized that the notice does not constitute an offer to sell and attached a legal opinion; it also highlighted progress in the OpRegen program with Roche/Genentech and received a buy recommendation from H.C. Wainwright with a $9.00 price target. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2003, Lineage Cell Therapeutics has already paid €0.0651 in dividends. The last payout was in December 2003.

Financials

In the last quarter, Lineage Cell Therapeutics had revenue of €936.67K and net profit of €1.3M

(EUR)	Jun 2026	YoY
Revenue	936.67K	60.07%
Gross profit	772.82K	66.59%
Net profit	1.3M	105.02%
EBITDA	1.52M	137.49%

Fundamentals

Metric	Value
Market capitalization	€243.14M
Number of shares	249.3M
52-week high/low	€1.80 - €0.86
Dividends	No
Beta	1.55
P/E ratio	-8.06
PEG ratio	0.20
P/B ratio	4.63
P/S ratio	21.53

Company profile

Lineage Cell Therapeutics, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und entwickelt neuartige Zelltherapien zur Behandlung degenerativer Erkrankungen in den Vereinigten Staaten und international. Das Unternehmen entwickelt OpRegen, eine Zellersatztherapie für das retinale Pigmentepithel, die sich in einer klinischen Phase I/IIa-Studie zur Behandlung der trockenen altersbedingten Makuladegeneration befindet; OPC1, eine Oligodendrozyten-Vorläuferzelltherapie, die sich in einer multizentrischen klinischen Phase I/IIa-Studie zur Behandlung akuter Rückenmarksverletzungen befindet; und VAC2, eine allogene Krebsimmuntherapie aus Antigen-präsentierenden dendritischen Zellen, die sich in einer klinischen Phase I-Studie zur Behandlung von nicht-kleinzelligem Lungenkrebs befindet. Das Unternehmen bietet auch Renevia an, ein Produkt für die Gesichtsästhetik. Darüber hinaus beschäftigt sich das Unternehmen mit der Erforschung und Entwicklung von therapeutischen Produkten für Netzhauterkrankungen, neurologische Erkrankungen und Störungen sowie für die Onkologie. Lineage Cell Therapeutics, Inc. hat eine Zusammenarbeit mit Orbit Biomedical, Ltd. Das Unternehmen war früher als BioTime, Inc. bekannt und änderte im August 2019 seinen Namen in Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics, Inc. wurde 1990 gegründet und hat seinen Hauptsitz in Carlsbad, Kalifornien.

Name	Lineage Cell Therapeutics
CEO	Brian Culley
Headquarters	Carlsbad, ca USA
Website	lineagecell.com
Sector	Consumer Staples
Industry	Food Products
IPO	03/05/1992
Employees	75